Mirion Technologies: Quiet Winner Of The Nuclear Upcycle

Mirion Technology Inc. (NYSE:MIR) is positioned to benefit from nuclear-friendly policies and rising power demand, reporting solid Q1-Q2 growth and raising FY25 guidance for revenue, EBITDA, free cash flow, and EPS. The company's cash profile is strengthening through recent GAAP profitability, strategic acquisitions exceeding $400M, margin expansion driven by its Medical segment's shift to high-margin software, and improved free cash flow from working capital discipline and debt optimization, including $400M in converts. Despite a premium valuation and leverage risk, sustained double-digit growth from modernization and an increasing software mix could deliver meaningful upside.

Analysis

Mirion Technology (NYSE:MIR) is strategically positioned to capitalize on favorable macro trends, including nuclear-friendly policies and a projected 20% increase in global power demand by 2030. The company's recent performance underscores this potential, with solid top- and bottom-line growth reported in the first half of the fiscal year, leading management to raise its full-year 2025 guidance for revenue, EBITDA, free cash flow, and EPS. Financial health is improving, evidenced by recent GAAP profitability and a stronger cash profile bolstered by over $400M in acquisitions. Margin expansion is a key driver, primarily stemming from the Medical segment's scaling and strategic shift toward higher-margin software, although this is partially offset by mix and project cost headwinds in the Nuclear & Safety segment. Furthermore, Mirion has improved its capital structure and liquidity through disciplined working-capital management, lower capex, and a debt refinancing that included a $400M 0.25% convertible note and a resized 2032 term loan, effectively cutting interest expenses and extending maturities. Despite these positive developments, the company's premium valuation and existing leverage risk are notable, though the potential for sustained double-digit growth from modernization projects and a growing software mix could provide meaningful upside.

Key Decisions for Investors

• Investors with a growth-oriented mandate should consider Mirion's exposure to the nuclear power secular trend, supported by its raised FY25 guidance and improving free cash flow.
• It is crucial to monitor the company's leverage and valuation metrics, as the current premium valuation requires sustained double-digit growth to be justified.
• Portfolio managers should closely track segment-level performance, particularly the margin trajectory in the Medical segment's software shift and any resolution of cost headwinds in the Nuclear & Safety division.